Article

More than 50,000 crystalenses implanted

Aliso Viejo, CA-Since FDA approval in 2003, more than 50,000 crystalens accommodating IOLs (eyeonics) have been implanted worldwide. Of these, 17,000 implants were with the crystalens SE second-generation lens (introduced in 2005), the company said in a prepared statement.

Aliso Viejo, CA-Since FDA approval in 2003, more than 50,000 crystalens accommodating IOLs (eyeonics) have been implanted worldwide. Of these, 17,000 implants were with the crystalens SE second-generation lens (introduced in 2005), the company said in a prepared statement.

"Demand for the crystalens by ophthalmologists and their patients has remained very strong, with implants up around 30% in the second quarter," said J. Andy Corley, eyeonics' chairman and chief executive officer. "This is due in part to our commitment that surgeons and patients alike see positive, hassle-free outcomes with crystalens implants.

"We are delighted that the adjustments to the design and the surgical protocol available with the crystalens SE have been received so positively, strengthening our market share in the premium lens channel," Corley added.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
Image credit: ©Ophthalmology Times
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
© 2025 MJH Life Sciences

All rights reserved.